Brooke Emerling PhD
Director and Associate ProfessorCancer Metabolism and Microenvironment Program
EmailLab Website
Emerling received her B.A. from the University of California Santa Cruz and her PhD in molecular and cellular biology from Northwestern University. Emerling did her postdoctoral training at Harvard Medical School. She then became an Instructor of Cancer Biology in Medicine at Weill Cornell Medical College in New York City, where she continued her research on lipid kinase signaling and cancer metabolism. In August 2016, Brooke joined the faculty at Sanford Burnham Prebys Medical Discovery Institute as an Assistant Professor in the Cancer Metabolism and Signaling Networks Program.
Breast Cancer Research Foundation – AACR Career Development Award for Translational Breast Cancer Research
Mary Kay Foundation Innovative Translational Grant Award
Department of Defense Breast Research Program Breakthrough Award
2014: NextGen Star – AACR Early-Career Speaker Award
2013-2016: Mastercard Ajay Banga Scientist Award
2013: AACR – Aflac Travel Fellowship Award
Related Disease
Breast Cancer, Cancer
Phenomena or Processes
Cancer Biology, Cancer Metabolism, Cell Signaling, Metabolic Processes, Signal Transduction
Research in the Emerling Lab is focused on understanding key signaling and metabolic pathways involved in the regulation of cellular function under pathological conditions such as cancer. Our research program centers around dissecting the roles of the family of non-canonical phosphatidylinositol kinases, called the phosphatidylinositol-5-phosphate 4-kinases (PI5P4Ks), in cancer metabolism using a multi-disciplinary approach integrating human, mouse, and worm models. Currently, a major research project in the Emerling Lab is determining the role of the PI5P4Ks in p53 mutant cancers, especially the triple-negative breast cancer subgroup where targeted therapies have not been effective.
The San Diego-based philanthropic organization has awarded $43 million in cancer research to date.
The funds will support Alicia Llorente Lope and Ambroise Manceau who study breast and pancreatic cancer.
Scientists at Sanford Burnham Prebys and Vanderbilt University uncover a new role for a neglected lipid that may play a…
By inhibiting one enzyme, scientists from Sanford Burnham Prebys can kill prostate cancer cells when other treatments can’t For the
The promoted faculty, all from the Institute’s NCI-designated Cancer Center, include Ani Deshpande, PhD, Brooke Emerling, PhD and Charles Spruck,…
After a promising breakthrough in cancer metabolism, the NIH is helping Sanford Burnham Prebys keep up the good work Brooke…
Lundquist MR, Goncalves MD, Loughran RM, Possik E, Vijayaraghavan T, Yang A, Pauli C, Ravi A, Verma A, Yang Z, Johnson JL, Wong JCY, Ma Y, Hwang KS, Weinkove D, Divecha N, Asara JM, Elemento O, Rubin MA, Kimmelman AC, Pause A, Cantley LC, Emerling BM
Mol Cell 2018 May 3 ;70(3):531-544.e9Sumita K, Lo YH, Takeuchi K, Senda M, Kofuji S, Ikeda Y, Terakawa J, Sasaki M, Yoshino H, Majd N, Zheng Y, Kahoud ER, Yokota T, Emerling BM, Asara JM, Ishida T, Locasale JW, Daikoku T, Anastasiou D, Senda T, Sasaki AT
Mol Cell 2016 Jan 21 ;61(2):187-98Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Wulf GM, Bell EL, Shim HS, Lamia KA, Rameh LE, Bellinger G, Sasaki AT, Asara JM, Yuan X, Bullock A, Denicola GM, Song J, Brown V, Signoretti S, Cantley LC
Cell 2013 Nov 7 ;155(4):844-57